Detection of mitomycin C-DNA adducts in human breast cancer cells grown in culture, as xenografted tumors in nude mice, and in biopsies of human breast cancer patient tumors as determined by 32P-postlabeling

Clinical Cancer Research

Volumn 7, Issue 4, 2001, Pages 1033-1042

  Warren, A J ^a   Mustra, D J ^a   Hamilton, J W ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; BISPECIFIC ANTIBODY; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DNA; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; FLUOXYMESTERONE; IMMUNOTOXIN; MEGESTROL ACETATE; METHOTREXATE; MITOMYCIN C; NAVELBINE; OXIDOREDUCTASE; PACLITAXEL; PHOSPHORUS 32; PREDNISONE; TAMOXIFEN; THIOTEPA; VINBLASTINE;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA ADDUCT; DNA REPAIR; DRUG CYTOTOXICITY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUDE MOUSE; PH; PRIORITY JOURNAL; QUANTITATIVE ASSAY; TISSUE OXYGENATION; TREATMENT OUTCOME; TUMOR BIOPSY; TUMOR XENOGRAFT;

AGED; ANIMALS; BIOPSY; BREAST NEOPLASMS; CLINICAL TRIALS; DNA ADDUCTS; DNA, NEOPLASM; FEMALE; GENOME; HUMANS; MICE; MICE, NUDE; MIDDLE AGED; MITOMYCIN; NEOPLASM TRANSPLANTATION; PHOSPHORUS RADIOISOTOPES; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0034909364     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. The mitomycin bioreductive antitumor agents: Cross-linking and alkylation of DNA as the molecular basis of their activity
2. Mitomycin. Ten years after approval for marketing
3. 32P-postlabeling: Time course for formation and removal of adducts and biochemical modulation
4. 2G interstrand cross-link in a model synthetic 23 base pair oligonucleotide DNA duplex
5. Suppression of P-glycoprotein expression and multi-drug resistance by DNA crosslinking agents
6. Distribution of Porfiromycin in EMT6 solid tumors and normal tissues of BALB/c mice
7. Effects of mitomycin C and carboplatin pretreatment on multidrug resistance-associated P-glycoprotein expression and on subsequent suppression of tumor growth by doxorubicin and paclitaxel in human metastatic breast cancer xenografted nude mice
8. Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice
9. Influence of regional location of the inoculation site and dietary fat on the pathology of MDA-MB-435 human breast cancer cell-derived tumors grown in nude mice
10. Suppression in expression of P-glycoprotein and other proteins associated with multidrug resistance (MDR) by mitomycin C in metastatic breast cancer patients. Preliminary results from a pilot clinical trial
11. Characterization of the DNA damage recognized by an antiserum elicited against cis-diamminedichloroplatinum(II)-modified DNA
12. DNA adducts of cisplatin and carboplatin in tissues of cancer patients
13. The unique sensitivity of walker rat tumour cells to disfunctional agents is associated with a failure to recover from inhibition of DNA synthesis and increased chromosome damage
14. DNA adducts from chemotherapeutic agents
15. Interactions of BMS-181174 and radiation: Studies with EMT6 cells in vitro and in solid tumors
16. Adducts of mitomycin C and DNA in EMT6 mouse mammary tumor cells: Effects of hypoxia and dicumarol on adduct patterns
17. Expression of 5-aminolaevulinate synthase and cytochrome P-450 mRNAs in chicken embryo hepatocytes in vivo and in culture
18. Structure of adduct X, the last unknown of the six major DNA adducts of mitomycin C formed in EMT6 mouse mammary tumor cells
19. Formation of a major DNA adduct of the mitomycin metabolite 2,7-diaminomitosene in EMT6 mouse mammary tumor cells treated with mitomycin C
20. Mitomycin C-DNA adducts generated by DT-diaphorase. Revised mechanism of the enzymatic reductive activation of mitomycin C
21. Enzymology of bioreductive drug activation
22. pH dependence of mitomycin C-induced crosslinking activity in EMT6 tumor cells
23. pH-dependent inactivation of DT-diaphorase by mitomycin C and porfiromycin
24. Enzymatic and pH modulation of mitomycin C-induced DNA damage in mitomycin C-resistant HCT 116 human colon cancer cells
25. Effect of pH on DNA alkylation by enzymeactivated mitomycin C and porfiromycin
26. Mitomycin C: A prototype bioreductive agent
27. Mitomycin C-an overview
28. New findings in the pharmacokinetic. Metabolic and drug-resistance aspects of mitomycin C
29. Mitomycin C (MMC) combined with paclitaxel (PCTX). A clinical and pharmacokinetic study
30. Correlation between induction of xenobiotic metabolism and DNA damage from chemical carcinogens in the chick embryo in vivo
31. Chromium(Vl)-induced DNA damage in chick embryo liver and blood cells in vivo
32. 32P analysis of DNA adducts in somatic and reproductive tissues of rats treated with the anticancer antibiotic mitomycin C
33. 32P-postlabeling analysis
34. Bulky endogenous DNA modifications (I-compounds): Possible structural origins and functional implications
35. Paclitaxel pharmacokinetics when preceded by mitomycin C as a modulator of multidrug resistance in patients with advanced carcinoma